Randomized phase III SIERRA trial of 131I-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed/refractory AML

Authors

Boglarka Gyurkocza, Memorial Sloan Kettering Cancer Center
Camille Abboud, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

9-19-2024

Volume

43

Issue

2

First Page

201

Last Page

213

Document Type

Open Access Publication

DOI

10.1200/JCO.23.02018

Rights and Permissions

Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol. 2025 Jan 10;43(2):201-213. doi: 10.1200/JCO.23.02018. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Gyurkocza, Boglarka; Abboud, Camille; and et al., "Randomized phase III SIERRA trial of 131I-apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed/refractory AML." Journal of Clinical Oncology. 43, 2. 201 - 213. (2024).
https://digitalcommons.wustl.edu/oa_4/4673

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.